세계의 분자진단 시장 : 기술, 제품, 용도, 최종 사용자별 예측(2025-2030년)

The Molecular Diagnostics Market was valued at USD 31.59 billion in 2023, expected to reach USD 36.30 billion in 2024, and is projected to grow at a CAGR of 15.82%, to USD 88.36 billion by 2030.

The scope of molecular diagnostics encompasses a wide range of tests that utilize molecular biology techniques to analyze genetic material and proteins to diagnose and monitor diseases, assess the risk of developing certain conditions, and determine prognosis. As a crucial tool in personalized medicine, its necessity lies in its precision and ability to provide early and accurate diagnosis, enabling tailored therapeutic strategies. Molecular diagnostics find applications in infectious disease detection, oncology, genetic testing, and pharmacogenomics, catering to end-users such as hospitals, laboratories, research institutions, and pharmaceutical companies. The market is influenced by increasing incidences of infectious diseases and cancer, technological advancements in molecular diagnostic techniques, and a growing focus on personalized medicine.

Recent opportunities emerge from the integration of artificial intelligence and machine learning with diagnostic platforms, enhancing data analysis and predictive capabilities. Strategic collaborations for assay development and increased government funding in pandemic preparedness also present growth avenues. However, the market faces limitations due to high costs of tests, stringent regulatory approvals, and the need for sophisticated infrastructure, which can restrict adoption particularly in low-resource settings. Developing standardized protocols and improving access in emerging markets are crucial steps to addressing these challenges.

Innovation areas with potential include point-of-care testing solutions, cost-effective sequencing technologies, and biomarker discovery that can lead to novel diagnostic tests. Partnerships between biotech firms and healthcare providers can expedite the development and implementation of these innovations. The molecular diagnostics market is intrinsically dynamic, driven by rapid technological evolution and a shift towards a more diagnostic-centric approach in healthcare. Businesses can strategically position themselves by focusing on expanding their assay portfolios to include rare diseases and by leveraging digital health technologies to optimize workflows and improve patient outcomes. Remaining adaptable to burgeoning scientific advancements and regulatory landscapes will be key to sustaining business growth in this field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Molecular Diagnostics Market

The Molecular Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • High prevalence of infectious diseases and various types of cancers prevalence rate of hospital-acquired infections
  • Escalation in government funding
  • Increasing demand for point of care diagnostics
• Market Restraints
  • Lack of clear and uniform regulatory framework
  • Inefficiency of trained professionals limiting the appropriate use of new molecular diagnostic technologies
• Market Opportunities
  • Technological advancements in molecular diagnostics along with increasing awareness towards early disease diagnosis
  • Rising number of R&D activities in the emerging economies
• Market Challenges
  • Delay in the approval of new molecular diagnostic tests
  • Stringent regulations associated with the approval process

Porter's Five Forces: A Strategic Tool for Navigating the Molecular Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Molecular Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Molecular Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Molecular Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Molecular Diagnostics Market

A detailed market share analysis in the Molecular Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Molecular Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Molecular Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Molecular Diagnostics Market

A strategic analysis of the Molecular Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Molecular Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ADT Biotech, Agilent Technologies Inc., Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc., Biocartis Group NV, bioMerieux SA, Danaher Corporation, DiaSorin S.p.A., Grifols S.A., Hologic Inc., Illumina, Inc., Johnson & Johnson, LabCorp, Myriad Genetics, Inc., Novartis AG, Roche Diagnostics Corporation, Siemens Healthineers, Sysmex Corporation by Oxford Gene Technology, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Molecular Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technology, market is studied across Chips and Microarrays, In Situ Hybridization, Mass Spectrometry (MS), PCR, and Sequencing.
• Based on Product, market is studied across Instruments and Reagents.
• Based on Application, market is studied across Blood Screening, Genetic Disease Screening, Human Leukocyte Antigen Typing, Infectious Disease, Microbiology, Oncology, and Pharmacogenomics.
• Based on End User, market is studied across Hospitals and Laboratories.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. High prevalence of infectious diseases and various types of cancers prevalence rate of hospital-acquired infections
    • 5.1.1.2. Escalation in government funding
    • 5.1.1.3. Increasing demand for point of care diagnostics
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of clear and uniform regulatory framework
    • 5.1.2.2. Inefficiency of trained professionals limiting the appropriate use of new molecular diagnostic technologies
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in molecular diagnostics along with increasing awareness towards early disease diagnosis
    • 5.1.3.2. Rising number of R&D activities in the emerging economies
  • 5.1.4. Challenges
    • 5.1.4.1. Delay in the approval of new molecular diagnostic tests
    • 5.1.4.2. Stringent regulations associated with the approval process
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Expanding use of next-generation sequencing in personalized medicine and targeted therapies
  • 5.2.2. Applications: Integration of molecular diagnostics in precision medicine for early intervention of infectious diseases
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Molecular Diagnostics Market, by Technology

• 6.1. Introduction
• 6.2. Chips and Microarrays
• 6.3. In Situ Hybridization
• 6.4. Mass Spectrometry (MS)
• 6.5. PCR
• 6.6. Sequencing

7. Molecular Diagnostics Market, by Product

• 7.1. Introduction
• 7.2. Instruments
• 7.3. Reagents

8. Molecular Diagnostics Market, by Application

• 8.1. Introduction
• 8.2. Blood Screening
• 8.3. Genetic Disease Screening
• 8.4. Human Leukocyte Antigen Typing
• 8.5. Infectious Disease
• 8.6. Microbiology
• 8.7. Oncology
• 8.8. Pharmacogenomics

9. Molecular Diagnostics Market, by End User

• 9.1. Introduction
• 9.2. Hospitals
• 9.3. Laboratories

10. Americas Molecular Diagnostics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Molecular Diagnostics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Molecular Diagnostics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Guardant Health launches Guardant360 TissueNext test with nearly 500 biomarkers
  • 13.3.2. QIAGEN and Myriad Genetics collaborate on Homologous Recombination Deficiency Test for Global Use
  • 13.3.3. Labcorp launches clinically validated ctDNA solution for early-stage colon cancer
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. ADT Biotech
• 3. Agilent Technologies Inc.
• 4. Becton, Dickinson, and Company
• 5. Bio-Rad Laboratories, Inc.
• 6. Biocartis Group NV
• 7. bioMerieux SA
• 8. Danaher Corporation
• 9. DiaSorin S.p.A.
• 10. Grifols S.A.
• 11. Hologic Inc.
• 12. Illumina, Inc.
• 13. Johnson & Johnson
• 14. LabCorp
• 15. Myriad Genetics, Inc.
• 16. Novartis AG
• 17. Roche Diagnostics Corporation
• 18. Siemens Healthineers
• 19. Sysmex Corporation by Oxford Gene Technology
• 20. Thermo Fisher Scientific Inc.